Abstract: Objective The aim of this study was to summarize the ultrasound manifestation of hepatic distomiasis and its clinical outcomes. Methods 30 patients with hepatic distomiasis and common bile duct obstruction were included in this study, and all came from the Department of Gastroenterology and General Surgery in our hospital between January 2012 and November 2018. All patients underwent ultrasonography, and the patients received praziquantel for treatment, and some of them received endoscopic retrograde cholangiao-pancreatography (ERCP) for bile duct obstruction after praziquantel therapy. Results The ultrasound manifestation of patients with hepatic distomiasis were the thickness of bile duct walls and intrahepatic bile duct dilation, often with common bile duct diseases; the successful rate by praziquantel therapy was 63.3%, and eleven patients received ERCP, all successful; at presentation, serum bilirubin, aspartate aminotransferase and alanine aminotransferase levels were (56.1±13.9)μmol/L, (151.2±67.8)U/L and (74.3±30.7)U/L, and all improved after treatment or operation 【(13.3±1.3)μmol/L, (91.5±39.2)U/L and (32.7±14.3)U/L, respectively, P<0.05】; post-operationally, acute pancreatitis developed in four patients and blood hyperamylase developed in five patients, and all recovered after two to ten day internal interventions. Conclusion The ultrasound features of hepatic distomiasis and biliary obstruction is characterized by thickening of the bile duct walls, and dilatation of intrahepatic bile ducts. The praziquantel treatment is efficacious in most patients and the intervention of ERCP also has a good outcomes in patients with bile duct obstruction and dilatation.

Key words: Hepatic distomiasis, Biliary obstruction, Ultrasound, Praziquantel, Diagnosis and treatment